

John David Norris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/743389/publications.pdf>

Version: 2024-02-01

48
papers

4,585
citations

117571

34
h-index

214721

47
g-index

51
all docs

51
docs citations

51
times ranked

5622
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Chemotype of Chemically Tractable Nonsteroidal Estrogens Based on a Thieno[2,3- <i>d</i>]pyrimidine Core. ACS Medicinal Chemistry Letters, 2022, 13, 1151-1158.	1.3	1
2	Next-Generation Endocrine Therapies for Breast Cancer. Journal of Clinical Oncology, 2021, 39, 1383-1388.	0.8	19
3	Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor- β degrader activity in antitumor efficacy. Breast Cancer Research and Treatment, 2020, 179, 67-77.	1.1	30
4	The Dysregulated Pharmacology of Clinically Relevant α ESR1 Mutants is Normalized by Ligand-activated WT Receptor. Molecular Cancer Therapeutics, 2020, 19, 1395-1405.	1.9	26
5	G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment, 2020, 180, 635-646.	1.1	32
6	The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Reports, 2019, 29, 889-903.e10.	2.9	40
7	Targeting mutant estrogen receptors. ELife, 2019, 8, .	2.8	6
8	HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer. Prostate, 2019, 79, 414-424.	1.2	39
9	Defining the molecular pharmacology of disease relevant estrogen receptor mutations for effective therapeutic targeting in breast cancer. FASEB Journal, 2019, 33, 815.4.	0.2	0
10	Neomorphic ER β Mutations Drive Progression in Breast Cancer and Present a Challenge for New Drug Discovery. Cancer Cell, 2018, 33, 153-155.	7.7	4
11	Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degradar (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. Journal of Medicinal Chemistry, 2018, 61, 2837-2864.	2.9	103
12	Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER β WT and ER β MUT Breast Cancer. Cancer Discovery, 2018, 8, 1176-1193.	7.7	81
13	CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. Molecular Cancer Research, 2017, 15, 660-669.	1.5	22
14	MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. Hormones and Cancer, 2017, 8, 69-77.	4.9	45
15	Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degradar for ER β Breast Cancer. Journal of Medicinal Chemistry, 2017, 60, 2790-2818.	2.9	36
16	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. Journal of Clinical Investigation, 2017, 127, 2326-2338.	3.9	40
17	Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer. Nature Chemical Biology, 2016, 12, 795-801.	3.9	15
18	Small Molecule Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. Angewandte Chemie - International Edition, 2015, 54, 9659-9662.	7.2	146

#	ARTICLE	IF	CITATIONS
19	Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4883-4887.	2.9	147
20	Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5121-5130.	3.2	126
21	Obesity, Cholesterol Metabolism, and Breast Cancer Pathogenesis. <i>Cancer Research</i> , 2014, 74, 4976-4982.	0.4	86
22	Bisphenol A affects androgen receptor function via multiple mechanisms. <i>Chemico-Biological Interactions</i> , 2013, 203, 556-564.	1.7	154
23	Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12178-12183.	3.3	43
24	Induction of Krüppel-Like Factor 5 Expression by Androgens Results in Increased CXCR4-Dependent Migration of Prostate Cancer Cells <i>in Vitro</i> . <i>Molecular Endocrinology</i> , 2009, 23, 1385-1396.	3.7	62
25	Differential Presentation of Protein Interaction Surfaces on the Androgen Receptor Defines the Pharmacological Actions of Bound Ligands. <i>Chemistry and Biology</i> , 2009, 16, 452-460.	6.2	47
26	The Homeodomain Protein HOXB13 Regulates the Cellular Response to Androgens. <i>Molecular Cell</i> , 2009, 36, 405-416.	4.5	183
27	Development of a Small-Molecule Serum- and Glucocorticoid-Regulated Kinase-1 Antagonist and Its Evaluation as a Prostate Cancer Therapeutic. <i>Cancer Research</i> , 2008, 68, 7475-7483.	0.4	182
28	Single-step purification of full-length human androgen receptor. <i>Nuclear Receptor Signaling</i> , 2005, 3, nrs.03001.	1.0	14
29	Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism. <i>Molecular Cell</i> , 2005, 18, 413-424.	4.5	225
30	Application of Random Peptide Phage Display to the Study of Nuclear Hormone Receptors. <i>Methods in Enzymology</i> , 2003, 364, 118-142.	0.4	14
31	A Negative Coregulator for the Human ER. <i>Molecular Endocrinology</i> , 2002, 16, 459-468.	3.7	79
32	Identification of a Negative Regulatory Surface within Estrogen Receptor β Provides Evidence in Support of a Role for Corepressors in Regulating Cellular Responses to Agonists and Antagonists. <i>Molecular Endocrinology</i> , 2002, 16, 1778-1792.	3.7	97
33	Connections and Regulation of the Human Estrogen Receptor. <i>Science</i> , 2002, 296, 1642-1644.	6.0	518
34	Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. <i>American Journal of Cardiology</i> , 2002, 90, F35-F43.	0.7	48
35	Definition of the Molecular and Cellular Mechanisms Underlying the Tissue-selective Agonist/Antagonist Activities of Selective Estrogen Receptor Modulators. <i>Endocrine Reviews</i> , 2002, 57, 295-316.	7.1	111
36	Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM. <i>Annals of the New York Academy of Sciences</i> , 2001, 949, 16-35.	1.8	34

#	ARTICLE	IF	CITATIONS
37	Modulation of Estrogen Receptor- β Transcriptional Activity by the Coactivator PGC-1. <i>Journal of Biological Chemistry</i> , 2000, 275, 16302-16308.	1.6	193
38	Development of peptide antagonists that target estrogen receptor-cofactor interactions. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 74, 327-335.	1.2	36
39	Comparative Analyses of Mechanistic Differences Among Antiestrogens ¹ . <i>Endocrinology</i> , 1999, 140, 5828-5840.	1.4	214
40	Dissection of the LXXLL Nuclear Receptor-Coactivator Interaction Motif Using Combinatorial Peptide Libraries: Discovery of Peptide Antagonists of Estrogen Receptors β and β ² . <i>Molecular and Cellular Biology</i> , 1999, 19, 8226-8239.	1.1	349
41	Enhancement of Estrogen Receptor Transcriptional Activity by the Coactivator GRIP-1 Highlights the Role of Activation Function 2 in Determining Estrogen Receptor Pharmacology. <i>Journal of Biological Chemistry</i> , 1998, 273, 6679-6688.	1.6	90
42	The Nuclear Corepressors NCoR and SMRT Are Key Regulators of Both Ligand- and 8-Bromo-Cyclic AMP-Dependent Transcriptional Activity of the Human Progesterone Receptor. <i>Molecular and Cellular Biology</i> , 1998, 18, 1369-1378.	1.1	242
43	Estrogenic Activity of a Dieldrin/Toxaphene Mixture in the Mouse Uterus, MCF-7 Human Breast Cancer Cells, and Yeast-Based Estrogen Receptor Assays: No Apparent Synergism*. <i>Endocrinology</i> , 1997, 138, 1520-1527.	1.4	113
44	Identification of a Third Autonomous Activation Domain within the Human Estrogen Receptor. <i>Molecular Endocrinology</i> , 1997, 11, 747-754.	3.7	90
45	BRCA1 expression is not directly responsive to estrogen. <i>Oncogene</i> , 1997, 14, 115-121.	2.6	109
46	Identification of a Third Autonomous Activation Domain within the Human Estrogen Receptor. <i>Molecular Endocrinology</i> , 1997, 11, 747-754.	3.7	30
47	Structure-Function Relationships of the Complement Regulatory Protein, CD59. <i>Blood Cells, Molecules, and Diseases</i> , 1996, 22, 281-296.	0.6	39
48	Identification of a New Subclass of Alu DNA Repeats Which Can Function as Estrogen Receptor-dependent Transcriptional Enhancers. <i>Journal of Biological Chemistry</i> , 1995, 270, 22777-22782.	1.6	205